1. First-Mover in Protein Sequencing • QSI is aiming to do for proteins what Illumina did for DNA. • Their Sapphire platform can potentially democratize proteomics by making it faster, cheaper, and more accessible. 2. Massive Market Opportunity • The proteomics market is expected to reach ~$80B by 2030. • Drug development, diagnostics, and personalized medicine all rely increasingly on protein-level data. 3. Platform Play, Not a One-Off Product • If successful, QSI could become a core platform in labs like Thermo Fisher or Illumina—leading to high-margin recurring revenue. 4. Tech Validation by Former Illumina Founder • Jonathan Rothberg, who founded Illumina and Butterfly Network, is behind QSI. His track record brings credibility.